Drug Trial Radar · NCT05486182
Impact of 18F-FES PET on the Therapeutic Treatment of Patients With Metastatic Breast Cancer
Last checked: Nov 20, 2026Latest source record: Nov 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
153
Actual
Start
Feb 8, 2022
Primary completion
Apr 18, 2025
Study completion Dec 26, 2025
Sponsor
- Lead sponsor
- GE HealthcareIndustry
- Sponsor type
- Industry
- Collaborators
- Simbec-Orion Group; Keosys
- First posted
- Aug 3, 2022
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Diagnostic
- FDA-regulated drug
- No
- Who can join
- Female only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a multi-center study in France to evaluate the impact of ESTROTEP PET/CT results on the therapeutic management of patients with metastatic breast cancer (MBC). Each patient will be screened to determine whether the patient meets all the inclusion criteria and none of the exclusion criteria. After inclusion, a standardized pre ESTROTEP PET/CT questionnaire will be completed by the investigators to evaluate the initial management plan. Patient will perform the ESTROTEP PET/CT examination at visit 2. A standardized post ESTROTEP PET/CT questionnaire will then be completed by the investigators. Patients will be followed for 12 months to evaluate their clinical status and standard of care investigations.
Conditions
- Metastatic Breast Cancer
Interventions
18F Fluoroestradiol Radiopharmaceutical with PET/CTDrug
Administration of one dose of 18F FES for PET/CT imaging
Primary outcomes
What the sponsor says the trial is designed to measure.
- To assess the impact of ESTROTEP PET/CT on metastatic breast cancer patients management, initially ER+ and HER2-, in relapse after first-line treatment combining hormone therapy.Time frame: Change from baseline therapeutic measure at 15 days after ESTROTEP PET/CT
Locations
11 sites in 1 country. Site status is shown where the registry gives one.
CGFL
Dijon, France
CHU Grenoble Alpes
La Tronche, France
CHU de Limoges - Dupuytren
Limoges, France
Centre Léon Bérard
Lyon, France
Institut du Cancer de Montpellier
Montpellier, France
Hôpital Américain de Paris
Neuilly-sur-Seine, France
Centre Antoine Lacassagne
Nice, France
Hôpital Tenon
Paris, France
Institut Curie
Paris, France
Institut Curie
Saint-Cloud, France
Institut Claudius Regaud Centre de Lutte Contre le Cancer
Toulouse, France
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.